DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Frequently asked questions
What sector does DexCom, Inc (DXCM-RM) operate in?
DexCom, Inc belongs to the Healthcare sector and operates in the Medical Devices industry.
What is DexCom, Inc (DXCM-RM) current stock price?
As of the latest data, DexCom, Inc stock price is RUB 503.00, with a previous close of RUB 503.00.
What is DexCom, Inc (DXCM-RM) current market capitalization?
DexCom, Inc market cap is approximately 33.00 billion.
What is DexCom, Inc (DXCM-RM) Earnings Per Share (EPS)?
The trailing EPS is RUB 162.41, and the forward EPS is RUB 3.13.
What is DexCom, Inc (DXCM-RM) Price-to-Earnings (P/E) ratio?
DexCom, Inc current P/E ratio is 0.54, with a forward P/E of 28.23.
What is DexCom, Inc (DXCM-RM) EBITDA?
DexCom, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 34.38 billion.
Does DexCom, Inc (DXCM-RM) pay dividends?
No. DexCom, Inc does not pay a dividend.
How did DexCom, Inc (DXCM-RM) perform in its most recent earnings report?
In the last report (September 30, 2026), DexCom, Inc posted an EPS surprise of 10.61% and a revenue surprise of 8,349.15%.
What is DexCom, Inc (DXCM-RM) beta (volatility) score?
DexCom, Inc has a beta of -0.104, indicating lower volatility than the overall market.
